Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

BACKGROUND: Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remission by this approach in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Hejin, Wang, Zhenguang, Wang, Yao, Liu, Yang, Dai, Hanren, Tong, Chuan, Guo, Yelei, Guo, Bo, Ti, Dongdong, Han, Xiao, Yang, Qingming, Wu, Zhiqiang, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558895/
https://www.ncbi.nlm.nih.gov/pubmed/31182121
http://dx.doi.org/10.1186/s13045-019-0741-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558895/
https://www.ncbi.nlm.nih.gov/pubmed/31182121
http://dx.doi.org/10.1186/s13045-019-0741-6

Ejemplares similares